Core Insights - NovaBridge Biosciences is focused on developing immuno-oncology agents for cancer treatment, with several projects in various clinical trial stages [1] - The company has established strategic partnerships with major players in the industry to enhance its research and development efforts [1] Price Target Analysis - The consensus price target for NovaBridge's stock has decreased from $7.75 to $7.00 over the past month, indicating a more cautious short-term outlook from analysts [2][5] - Despite the recent decrease, the price target has remained stable over the past year, suggesting a consistent long-term view of the company's potential [2] Comparative Analysis with IMab - IMab has been upgraded to a Zacks Rank 2 (Buy), with a new price target of $8 set by analyst Kumaraguru Raja, reflecting increased optimism about its earnings potential [3][5] - The contrasting outlooks for NovaBridge and IMab highlight varied analyst sentiments based on recent developments in the biotech sector [4][5]

Core Insights - Milestone Scientific Inc. reported continued progress in operational transformation and growth strategy across its dental and medical segments, with a focus on building a leaner organization for sustained growth and improved profitability [1][2]. Financial Performance - For Q3 2025, revenues were approximately $2.4 million, a slight decrease from $2.5 million in Q3 2024, primarily due to lower domestic dental sales, partially offset by higher international dental sales and recurring medical revenue [3]. - Gross profit for Q3 2025 was approximately $1.6 million, or 70% of revenue, compared to $1.8 million, or 73% of revenue, in Q3 2024 [3]. - The operating loss for Q3 2025 was approximately $(1.1) million, an improvement of approximately $0.3 million, or 23%, from $(1.5) million in Q3 2024, attributed to lower selling, general, and administrative expenses [3]. - The net loss for Q3 2025 was approximately $(1.2) million, or $(0.01) per share, compared to a net loss of $(1.5) million, or $(0.02) per share, in Q3 2024 [3]. Year-to-Date Results - For the nine months ended September 30, 2025, revenues were approximately $6.9 million, an increase of approximately $0.3 million, or 5%, from $6.6 million in the same period of 2024, driven by growth in international dental sales and higher recurring revenue from the medical segment [4]. - Gross profit for the nine months ended September 30, 2025, was approximately $4.9 million, or 71% of revenue, consistent with the previous year [4]. - The operating loss for the nine months ended September 30, 2025, was approximately $(4.6) million, slightly improved from $(4.7) million in the same period of 2024 [4]. - The net loss for the nine months ended September 30, 2025, was approximately $(4.6) million, or $(0.06) per share, compared to a net loss of $(2.7) million, or $(0.03) per share, in the same period of 2024 [4]. Cash Position - As of September 30, 2025, the company reported cash and cash equivalents of approximately $1.3 million and working capital of approximately $3.1 million [5]. Strategic Initiatives - The company is expanding its direct sales programs in North America and securing new international registrations for its STA® Single Tooth Anesthesia System, while enhancing its omnichannel digital marketing strategy [2]. - There is growing utilization and recurring revenue from CompuFlo® disposables, with increasing interest from hospitals and international distributors [2]. - The company is advancing its reimbursement strategy for CompuFlo®, focusing on securing Medicare payment-rate assignments and expanding commercial coverage, which are seen as key enablers for broader adoption [2].

ROSELAND, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today announced that it will host a conference call at 8:30 AM Eastern Time on Friday, November 14th, 2025, to discuss the company’s financial results for the third quarter ended September 30, 2025, as well as the company’s corporate progress and other developments. The conference call will be available via telep ...

Core Viewpoint - Milestone Scientific Inc. will host a conference call to discuss its financial results for Q2 2025 and corporate developments [1] Group 1: Conference Call Details - The conference call is scheduled for 8:00 AM Eastern Time on August 15, 2025 [1] - U.S. callers can dial toll-free 888-506-0062, while international callers can use +1 973-528-0011 with access code 470429 [2] - An audio replay will be available until August 29, 2025, accessible via 877-481-4010 for U.S. callers and +1 919-882-2331 for international callers with access code 52876 [3] Group 2: Company Overview - Milestone Scientific Inc. is a technology-focused medical research and development company specializing in innovative injection technologies for medical, dental, and cosmetic applications [4] - The company’s computer-controlled systems aim to enhance injection precision, efficiency, and patient comfort and safety [4] - The proprietary DPS Dynamic Pressure Sensing Technology is utilized to regulate flow rate and monitor pressure during subcutaneous drug delivery [4]

Core Insights - Milestone Scientific Inc. has appointed Jason Papes as Senior Vice President, Global Head of Sales and Marketing, effective immediately, bringing over 30 years of experience in the healthcare and medical technology sectors [1][2] Company Overview - Milestone Scientific Inc. is a technology-focused medical research and development company that specializes in innovative injection technologies and instruments for medical and dental applications [8] Leadership Experience - Jason Papes has extensive experience in sales, marketing, and business development within the healthcare industry, having held leadership roles at large-cap medical technology companies and entrepreneurial ventures [2][3] - His previous roles include executive positions at Stryker Imaging and Brainlab, where he led significant commercial expansions and market share growth [4] Strategic Initiatives - Papes joins Milestone at a critical time as the company rolls out the CompuFlo® Epidural System, having made progress in establishing procedural payment pathways, including Medicare Part B payment rates under CPT® code 0777T [5] - The company is also advancing growth initiatives in its dental segment, focusing on increasing adoption of the STA Single Tooth Anesthesia® System [6] Leadership Commentary - Eric Hines, CEO of Milestone Scientific, emphasized Papes' leadership experience and understanding of the provider and payer landscape as key assets for the company's growth phase [7] - Papes expressed excitement about joining a team committed to innovation and patient safety, aiming to broaden the company's reach and drive value for stakeholders [7]

Core Insights - Milestone Scientific Inc. has appointed Eric C. Hines as the new Chief Executive Officer, effective immediately, to drive the company's next phase of commercial execution [1][3] Company Overview - Milestone Scientific Inc. is a technology-focused medical research and development company that specializes in innovative injection technologies for medical and dental applications [4] - The company utilizes its proprietary DPS Dynamic Pressure Sensing Technology platform to enhance the precision and efficiency of injections, thereby improving patient comfort and safety [4] Leadership Experience - Eric C. Hines brings over 25 years of leadership experience in scaling sales-driven enterprise software companies, with a notable track record in the healthcare sector [2] - Prior to joining Milestone, Hines served as President of North America at Ex Libris, where he successfully increased annual revenue from approximately $50 million to over $100 million [2] Strategic Goals - The company aims to accelerate the adoption of its CompuFlo technology, which has made significant progress in reimbursement, including Medicare Part B payment rates under CPT code 0777T [3] - Hines expressed a commitment to expanding Milestone's presence in both medical and dental markets, as well as pursuing new clinical indications and global opportunities [3] Market Opportunities - There are compelling opportunities identified in the dental segment, particularly with Milestone's STA system, which is noted for its differentiation in the market [3] - The company is focused on leveraging recent reimbursement achievements to support expanded commercial adoption of its technologies [3]